



Ref: BHL/ STEX 2/ 2025-26

Date: 05th April 2025

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001	National Stock Exchange of India Limited 5 th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051
Scrip Code: 539872	Symbol: BAJAJHCARE

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015

We wish to inform you that Bajaj Healthcare Limited, has successfully acquired Corporate Debtor, Genrx Pharmaceuticals Private Limited (in Liquidation) as going concern vide Sale Certificate dated 04th April 2025 issued by Official Liquidator.

Pursuant to provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 & the Company's code of Internal Procedures and Conduct for Regulating, monitoring & reporting of trading in securities, the Trading window for dealing in securities of the Bajaj Healthcare Limited shall continue to remain closed for all the Directors and Designated Employees in terms of our earlier disclosure dated 25th March 2025.

The details as required under Regulation 30 of SEBI (LODR) Regulation, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD-2/CIR/P/0155 dated November 11, 2024 are enclosed as "**Annexure-I**".

Kindly acknowledge and take the same on record.

Thanking You,

For and behalf of Bajaj Healthcare Limited

Monica Tanwar
Company Secretary & Compliance Officer

Annexure-I
Details required under the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD-2/CIR/P/0155 dated November 11, 2024

Sr. No	Particulars	Remarks
a)	Name of the target entity, details in brief such as size, turnover etc	Genrx Pharmaceuticals Private Limited (in Liquidation)
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	Not Applicable.
c)	Industry to which the entity being acquired belongs	Pharmaceuticals
d)	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Expansion of Business in the same line of business.
e)	Brief details of any governmental or regulatory approvals required for the acquisition	FDA approval or any other governmental or regulatory approvals for manufacturing pharmaceutical formulation products.
f)	Indicative time period for completion of the acquisition	3-6 months
g)	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash consideration
h)	Cost of acquisition and/or the price at which the shares Corporate Debtor are acquired	Rs. 10,85,00,000/-
i)	Percentage of shareholding / control acquired and / or number of shares acquired	Acquisition of 100% control
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<ol style="list-style-type: none"> 1. Products/line of business acquired: <u>Pharmaceutical formulation manufacturing facilities</u> 2. Date of incorporation: <u>24.12.2009</u> 3. History of last 3 years turnover: <u>Company was in liquidation since 2020</u> 4. Country in which the acquired entity has presence and any other significant information: <u>India</u>